thierryvandendriessche.com Report : Visit Site

Technical data of the thierryvandendriessche.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host thierryvandendriessche.com. Currently, hosted in United Kingdom and its service provider is Fast Hosts Ltd .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/7.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

professor in medicine call +32-477-529653 email: [email protected] download short cv | extensive cv news recipient of 2012 outstanding achievement award awarded by the european society of gene & cell therapy (www.esgct.eu) current position professor in medicine free university of brussel (vub) www.vub.ac.be professor in medicine university of leuven (kul) www.kuleuven.be member committee of advanced therapeutics european medicines agency www.ema.europa.eu education 1987 - 1992 ph.d. free university of brussel (vub); maxima cum laude (with felicitation of the jury) 1989 - 1991 m.sc. in molecular biology and biotechnology free university of brussel (vub); maxima cum laude 1983 - 1987 m.sc. in biology free university of brussel (vub); maxima cum laude scientific rational research program it is widely anticipated that improved gene therapy approaches will yield new treatments and cures for hereditary, acquired and complex diseases. convincing evidence continues to emerge from clinical trials that gene therapy is yielding therapeutic effects in patients suffering from a wide range of diseases. it is therefore essential to continue to invest in gene and cell therapy to address some of the outstanding questions and overcome the remaining challenges. research vision and objectives (i) applied translational research: to develop and validate gene and cell therapy for major health- and life-threatening diseases. to understand the molecular, cellular and immune mechanisms that influence the outcome of different gene/cell therapy approaches. to conduct translational gene therapy studies in large animal models in anticipation of moving forward to the clinic and initiate a phase i clinical trial. (ii) hypothesis-driven fundamental research: to unravel the molecular mechanisms and pathways underlying various (patho)physiologic processes important in human health and disease. (iii) technology development: to consolidate a broad state of the art technology platform based on the latest viral and non-viral vector systems. priority programs download the detailed research program the main focus of our current research program in molecular medicine is to apply this conceptual framework in the context of liver-related pathology. in particular, we primarily focus on hereditary disorders (hemophilia), acquired liver disease (hepatitis), liver inflammation and liver cancer. awards 1989 first prize national university competition 1990 recipient "belgian work against cancer" award 1995 second prize international competition of the european working group on gene therapy (ewgt) 1999 pharmacia & upjohn award for innovative medical research (€25000) 1999 young investigator award of the international society for thrombosis and hemostasis (isth) 1999 young investigator award of the european society of gene therapy 2002 international johann lucas schönlein award (€5000) for thrombosis & hemostasis 2006 sanofi-aventis prize for research in thrombosis, hemostasis & vascular biology (€12500) 2007 scientific prize belgian royal academy of medicine (r. secq & a. houssiau award) (€5000) 2007 bayer schering hemophilia special project award 2009 excellence in research award american society in gene & cell therapy (phd student/i.petrus) 2009 molecule of the year award : prestigious world-wide selection by ismcbbpr 2011 bayer schering hemophilia special project award 2012 prize of the royal academy of belgium – prof. marc verstraete award ($14,000) 2012 top abstract selection (out of nearly 2000 participants) - american society in gene & cell therapy department of gene therapy & regenerative medicine department director prof. dr. marinee chuah department co-director dr. janka matrai (phd) post-doctoral fellow dr. melvin rincon (md) phd student dr. kshitiz singh (md) phd student mariana loperfido (msc) phd student mario di matteo (msc) phd student sumitava dastidar (msc) phd student nisha nair (msc) phd student shilpita sarcar (msc) phd student hui wang phd student laura kremer phd student ermira samara-kuko (msc) research assistant brenda amondi msc student jessica willems msc student omid ghandeharian msc student funding inther eu framework program 6 (noe): clinigene eu framework program 7 (ip): persist iwt fwo cellectis johnson & johnson association francaise contre les myopathies (afm) cancer foundation (stichting tegen kanker) european hematology association bayer actogenix selected publications in chronological order; only some selected papers with impact factor > 10 are shown). scientific output consists of about 100 publications: blood (2000) 96 (3) 958-965 a novel cause of mild/moderate hemophilia a: mutations scattered in the factor viii c1 domain reduce factor viii binding to von willebrand factor. (i.f.: 10; cit.: 32) jacquemin, m., lavend'homme, r., benhida, a., vanzieleghem, b., d'oiron, r., lavergne, j.m., brackmann, h.h., schwaab, r., vandendriessche, t., chuah, m.k.l., hoylaerts, m., gilles, j.g., peerlinck, k., vermylen, j., saint-remy, j.m. download blood (2000) pdf nat med (2001) 7 (5) 575-83 synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. (i.f.27.9 ; cited: 512) carmeliet, p., moons l., luttun, a., vincenti, v., compernolle, v., de mol, m., wu, y., bono, f., devy, l., beck, h., scholz, d., acker, t., dipalma, t., dewerchin, m., noel, a., stalmans, i., barra, a., blacher, s., vandendriessche, t., ponten, a., eriksson, u., plate, k.h., foidart, j.m., schaper, w., charnock-jones, d.s., hicklin, d.j., herbert, j.m., collen, d., persico, m.g. download nat med (2001) pdf blood (2002) 100 (3) 813-822 lentiviral vectors containing the hiv-1 central polypurine tract can efficiently transduce non-dividing hepatocytes and antigen-presenting cells in vivo. (i.f.: 10.1; cit.: 115) vandendriessche, t., thorrez, l., naldini, l., follenzi, a., moons, l., berneman, z., collen, d., and chuah, m.k.l. download blood (2002) pdf blood (2003) 101 (5) 1734-1743 therapeutic factor viii levels and negligible toxicity in mouse and dog models of hemophilia a following gene therapy with high-capacity adenoviral vectors. (i.f.: 10.1; cit.: 74) chuah, m.k.l., schiedner, g., thorrez, l., brown, b., johnston, m., hertel, s., lillicrap, d., collen, d., vandendriessche, t. §, kochanek, s.,§corresponding author. download blood (2003) pdf nat. biotech (2003) 21 (8) 885-890 nanoparticles for the delivery of genes and drug into hepatocytes. (i.f.: 17.7; cit.: 72) yamada, t., iwasaki, y., tada, h., iwabuki, h., chuah, m.k.l., vandendriessche, t., kondo, a., ueda, m., seno, m., tanizawa, k., and kuroda, s. download nat. biotech (2003) pdf blood (2006) 107 (12) 4728-36 phenotypic correction of von willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von willebrand factor. (i.f.: 10.4; cit.:10) de meyer, s.f., vanhoorelbeke, k., chuah, m.k., pareyn, i., gillijns, v., hebbel, r.p., collen, d., deckmyn, h., vandendriessche, t. download blood (2006) pdf nat. genet. (2008) 40 (2) 170-80 deficiency or inhibition of oxygen sensor phd1 induces hypoxia tolerance by reprogramming basal metabolism. (i.f.: 30.3; cit.: 60) aragones, j., schneider, m., van geyte, k., fraisl, p., dresselaers, t., mazzone, m., dirkx, r., zacchigna, s., lemieux, h., ,jeoung, n.h., lambrechts, d., bishop, t., lafuste, p., diez-juan, a., harten, s.k., van noten, p., de bock, k., willam, c., tjwa, m., grosfeld, a., navet, r., moons, l., vandendriessche, t., deroose, c., wijeyekoon, b., nuyts, j., jordan, b., silasi-mansat, r., lupu, f., dewerchin, m., pugh, c., salmon, p., mortelmans, l., gallez, b., gorus, f., buyse, j., sluse, f., harris, r.a., gnaiger, e., hespel, p., van hecke, p., schuit, f., van veldhoven, p., ratcliffe, p., baes, m., maxwell, p., carmeliet, p. download nat. genet. (2008) pdf nat. genet. (2009) 1 (6) 753-61 molecular evolut

URL analysis for thierryvandendriessche.com

http://www.thierryvandendriessche.com/pdf/blood-2000.pdf
http://www.thierryvandendriessche.com/pdf/nat-biotech-2003.pdf
http://www.thierryvandendriessche.com/pdf/blood-2006.pdf
http://www.thierryvandendriessche.com/pdf/thierry-vandendriessche-short-cv.pdf
http://www.thierryvandendriessche.com/pdf/nat-genet-2008.pdf
http://www.thierryvandendriessche.com/pdf/blood-2002.pdf
http://www.thierryvandendriessche.com/pdf/blood-2009.pdf
http://www.thierryvandendriessche.com/pdf/hepatology_all_online_files.pdf
http://www.thierryvandendriessche.com/pdf/nat-genet-2009.pdf
http://www.thierryvandendriessche.com/pdf/thierry-vandendriessche-full-cv.pdf
http://www.thierryvandendriessche.com/pdf/blood-2003.pdf
http://www.thierryvandendriessche.com/pdf/plos-biol-2009-feb.pdf
http://www.thierryvandendriessche.com/pdf/nat-med-2001.pdf
http://www.thierryvandendriessche.com/pdf/circulation-2009.pdf
http://www.thierryvandendriessche.com/pdf/outstandingachievementaward2012-esgct.pdf

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Whois Server Version 2.0

Domain names in the .com and .net domains can now be registered
with many different competing registrars. Go to http://www.internic.net
for detailed information.

Domain Name: THIERRYVANDENDRIESSCHE.COM
Registrar: 123-REG LIMITED
Sponsoring Registrar IANA ID: 1515
Whois Server: whois.123-reg.co.uk
Referral URL: http://www.meshdigital.com
Name Server: NS.123-REG.CO.UK
Name Server: NS2.123-REG.CO.UK
Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Updated Date: 03-mar-2017
Creation Date: 10-mar-2010
Expiration Date: 10-mar-2019

>>> Last update of whois database: 2017-07-17T17:05:09Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR 123-REG LIMITED

  REFERRER http://www.meshdigital.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =thierryvandendriessche.com

  PORT 43

  TYPE domain

DOMAIN

  NAME thierryvandendriessche.com

NSERVER

  NS.123-REG.CO.UK 212.67.202.2

  NS2.123-REG.CO.UK 62.138.132.21

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

  CHANGED 2017-03-03

  CREATED 2010-03-10

  EXPIRES 2019-03-10

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .